Clinical Trial News and Research

RSS

Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes

Depomed, Inc. announced today that it has completed enrollment of Breeze 3, the company's pivotal Phase 3 clinical trial evaluating Serada for the non-hormonal treatment of menopausal hot flashes.

3 Mar 2011

Lixte receives $244,479.25 U.S. government grant for QTDP program

Lixte Biotechnology Holdings announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project.

3 Mar 2011

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

EpiCept Corporation today announced the Company has identified a statistically significant survival benefit in a subgroup of Acute Myeloid Leukemia patients in its previous Phase III trial with Ceplene administered with low-dose interleukin-2.

3 Mar 2011

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.

3 Mar 2011

Cyberonics third quarter net sales increase 15.3% to $47.1 million

Cyberonics, Inc., a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.

2 Mar 2011

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.

2 Mar 2011

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2010.

2 Mar 2011

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

2 Mar 2011

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

The National Eye Institute and Food and Drug Administration are sponsoring a conference to determine how functional vision-related endpoints for clinical trials of visual prostheses will be analyzed and correlated with objective measures of visual acuity, visual fields and contrast sensitivity.

2 Mar 2011

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) has completed the first two transcatheter aortic valve implants (TAVI) ever achieved in Michigan. The procedures are a part of CVI's participation in the Medtronic CoreValve® U.S. Clinical Trial. This multi-state trial will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis.

2 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Health benefits of herbal teas no longer a folklore

Those who enjoy the caffeinated lift that comes from drinking traditional coffees and teas may tend to overlook the benefits of drinking herbal infusions. Now, as explained in this month's issue of Agricultural Research magazine, the idea that herbal teas may provide a variety of health benefits is no longer just folklore.

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

New CPR method improves long-term survival rates in patients with cardiac arrest by 50%

A five-year clinical trial led by University of Minnesota Medical School researchers has led to a new method of cardiopulmonary resuscitation that improves long-term survival rates with good brain function by 50 percent.

1 Mar 2011

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

IRX Therapeutics, a developer of immune therapies to make cancer treatments better, announced today it has signed a research collaboration agreement with one of the world's leading research-based pharmaceutical companies.

1 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

High blood pressure medications useful even in those without hypertension: Study

Researchers have studied existing evidence to suggest that people who have had a stroke or a heart attack might benefit from taking blood pressure medications, even if they do not have high blood. They noted that for every 1,000 people taking the drugs in clinical trials, on average 15 fewer died from heart disease than when the patients got dummy treatment. The study however could not explain the cause for this benefit. The study, which was funded by Tulane University and the National Institutes of Health, was published in the March 2 issue of the Journal of the American Medical Association.

1 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

International conference to address pediatric congenital cataract treatment in New York City

An international conference addressing the treatment of children born with a cataract will take place in New York City on Friday, March 11, 2011.

1 Mar 2011

Clinical Trial News and Research

Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes

Lixte receives $244,479.25 U.S. government grant for QTDP program

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Cyberonics third quarter net sales increase 15.3% to $47.1 million

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

Health benefits of herbal teas no longer a folklore

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

New CPR method improves long-term survival rates in patients with cardiac arrest by 50%

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

High blood pressure medications useful even in those without hypertension: Study

QLT fourth quarter revenues decrease 7.3% to $10.0 million

International conference to address pediatric congenital cataract treatment in New York City

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer